Zydus muscular dystrophy drug receives FDA final approval

The drug is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older and is a reference listed equivalent of Emflaza.

Ahmedabad: Indian drug maker Zydus Lifesciences has received final approval from the United States Food and Drug Administration (US FDA) to manufacture Jaythari(Deflazacort) tablets, indicated for the treatment of Duchenne muscular dystrophy.

The approved drug 'Deflazacort' is a corticosteroid indicated for the treatment of a rare disorder of the Central Nervous System (CNS) called Duchenne muscular dystrophy (DMD) in patients 5 years of age and older and is a reference listed equivalent of Emflaza.

As per Zydus release the drug will be manufactured at its Italy facility n Doppel Farmaceutici S.r.l

Post this approval the Indian drug maker now has 424 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04.

News Source:

https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/zydus-muscular-dystrophy-drug-receives-fda-final-approval/120275951?utm_source=whatsapp_web&utm_medium=social&utm_campaign=socialsharebuttons